Literature DB >> 3934744

The postoperative fibrinolytic shutdown: a rapidly reverting acute phase pattern for the fast-acting inhibitor of tissue-type plasminogen activator after trauma.

C Kluft, J H Verheijen, A F Jie, D C Rijken, F E Preston, H M Sue-Ling, J Jespersen, A O Aasen.   

Abstract

The plasma activity level of the recently discovered fast-acting inhibitor of tissue-type plasminogen activator (t-PA) was found to be temporarily increased after surgery, myocardial infarction and severe trauma. Detailed analysis of the postoperative period revealed simultaneously increased t-PA antigen and inhibition and decreased t-PA activity only on the first postoperative day. These changes were more rapid than those in fibrinogen and C-reactive protein. It is concluded that t-PA inhibition shows the most rapidly changing pattern observed so far in response to trauma. The postoperative fibrinolytic shutdown in blood fibrinolytic activity can be ascribed to a primary increase in t-PA inhibitor levels.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3934744     DOI: 10.3109/00365518509155267

Source DB:  PubMed          Journal:  Scand J Clin Lab Invest        ISSN: 0036-5513            Impact factor:   1.713


  37 in total

Review 1.  Perioperative cardiac events in patients undergoing noncardiac surgery: a review of the magnitude of the problem, the pathophysiology of the events and methods to estimate and communicate risk.

Authors:  P J Devereaux; Lee Goldman; Deborah J Cook; Ken Gilbert; Kate Leslie; Gordon H Guyatt
Journal:  CMAJ       Date:  2005-09-13       Impact factor: 8.262

2.  Plasminogen activator inhibitor and von Willebrand factor in polymyalgia rheumatica.

Authors:  A Uddhammar; S Rantapåå-Dahlqvist; T K Nilsson
Journal:  Clin Rheumatol       Date:  1992-06       Impact factor: 2.980

3.  Distribution of plasminogen activator inhibitor (PAI-1) in tissues.

Authors:  A J Simpson; N A Booth; N R Moore; B Bennett
Journal:  J Clin Pathol       Date:  1991-02       Impact factor: 3.411

4.  [Uncritical use of tranexamic acid in trauma patients : Do no further harm!]

Authors:  M Maegele
Journal:  Unfallchirurg       Date:  2016-11       Impact factor: 1.000

Review 5.  Fibrinolysis Shutdown in Trauma: Historical Review and Clinical Implications.

Authors:  Hunter B Moore; Ernest E Moore; Matthew D Neal; Forest R Sheppard; Lucy Z Kornblith; Dominik F Draxler; Mark Walsh; Robert L Medcalf; Mitch J Cohen; Bryan A Cotton; Scott G Thomas; Christine M Leeper; Barbara A Gaines; Angela Sauaia
Journal:  Anesth Analg       Date:  2019-09       Impact factor: 5.108

6.  Induction of plasminogen activator inhibitor 1 gene expression in murine liver by lipopolysaccharide. Cellular localization and role of endogenous tumor necrosis factor-alpha.

Authors:  C Fearns; D J Loskutoff
Journal:  Am J Pathol       Date:  1997-02       Impact factor: 4.307

7.  Does Tranexamic Acid Improve Clot Strength in Severely Injured Patients Who Have Elevated Fibrin Degradation Products and Low Fibrinolytic Activity, Measured by Thrombelastography?

Authors:  Hunter B Moore; Ernest E Moore; Michael P Chapman; Kirk C Hansen; Mitchell J Cohen; Frederic M Pieracci; James Chandler; Angela Sauaia
Journal:  J Am Coll Surg       Date:  2019-03-29       Impact factor: 6.113

8.  Interleukin-6 and coagulation-fibrinolysis fluctuations after laparoscopic and conventional cholecystectomy.

Authors:  G Vander Velpen; F Penninckx; R Kerremans; J Van Damme; J Arnout
Journal:  Surg Endosc       Date:  1994-10       Impact factor: 4.584

9.  Type 1 plasminogen activator inhibitor gene expression following partial hepatectomy.

Authors:  J Schneiderman; M Sawdey; H Craig; T Thinnes; G Bordin; D J Loskutoff
Journal:  Am J Pathol       Date:  1993-09       Impact factor: 4.307

10.  Toxicogenomic analysis of mainstream tobacco smoke-exposed mice reveals repression of plasminogen activator inhibitor-1 gene in heart.

Authors:  Sabina Halappanavar; Martin R Stampfli; Lynn Berndt-Weis; Andrew Williams; George R Douglas; Carole L Yauk
Journal:  Inhal Toxicol       Date:  2009-01       Impact factor: 2.724

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.